🚨Our Nov issue is live - thelancet.com/issue/S1470-...
📊Articles: #breastcancer, #NSCLC, #prostatecancer, #melanoma
📰 Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO)
✨️ New review article landed ✨️
Very excited to share the news that our latest review into genetically engineered TILs has just been published in the @thelancetoncol.bsky.social
Many thanks to Özcan Met, Joel, and Inge Marie for their help in writing this!
www.sciencedirect.com/science/arti...
In these disease sates, we see low HLA Class I expression, and high NK-cell abundance, along with other insights into the immune infiltrations that expand our knowledge of this rare form of cancer of the eye.
In this paper, we show the feasibility of analysing immune infiltrations in primary uveal melanoma, particularly in the less well studied low-risk disease that do not normally undergo enucleation, through the use of Transvitreal Retinochoroidal (fine needle) Biopsies.
Happy to share the new article titled 'Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease' published this week in Investigative Opthalmology & Visual Science.
iovs.arvojournals.org/article.aspx...
Looking forward to seeing the peer reviewed paper of this preprint, as highlighted by @natrevimmunol.bsky.social
Method of engineering TILs using pMHC pseuodtyped retroviruses!
www.biorxiv.org/content/10.1...
They are similar to MAIT cells only in that they recognise MR1, so we don't think it is quite correct to call them MAIT. But they're definitely in the same family!
A follow up study to the Nature Immunology paper we published on the MR1-restricted T-cells (MC.7.G5) that respond to cancer! This time, cancer specific recognition of cancer cell lines through the use of a semi-invariant TCR containing a TRAJ42 segment and a CAXYGGSQGNLIF TCRα motif.
MAIT cell are defined by their expression of CD161 and having a TRAV1-2 containing TCR-alpha chain, and are highly present in the mucosa. These cancer-restricted T-cells do not posses any of these properties.
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months. The drug attaches to the lattice-like capsid proteins that shield the virus’s genetic material—a mechanism that could inspire other antivirals. Lenacapavir could help end the HIV/AIDS epidemic, but that will hinge on access for those who need it most.
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.
Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn